Research programme: cancer therapeutics - BerGenBio

Drug Profile

Research programme: cancer therapeutics - BerGenBio

Alternative Names: BGB 001; BGB 002 target; BGB 003; BGB 109; BGB 10C9; BGB 149; BGB-101

Latest Information Update: 02 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BerGenBio
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Pancreatic cancer

Most Recent Events

  • 10 Mar 2014 BerGenBio receives grant from Research Council of Norway (BIA) for Cancer therapeutic development
  • 05 Feb 2014 Preclinical development is ongoing in Norway
  • 31 Oct 2011 Preclinical trials in Cancer in Norway (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top